Group 1 - Tsugami Machine Tool China (01651) saw a rise of over 5.4% due to increased demand for high-precision machine tools in emerging sectors like new energy vehicles and artificial intelligence as China's economy gradually recovers [1] - Black Sesame Intelligence (02533) increased by over 2.2% after announcing that its flagship product, the Huashan A1000 automotive-grade high-performance driving assistance chip, has been successfully integrated into Desay SV's new low-speed unmanned vehicle brand "Chuanxing Zhiyuan" S6 series [1] - Zai Xin Bio-B (02509) rose over 5.8% after receiving clinical trial approval for its self-developed long-acting dual antibody QX027N injection, intended for the treatment of asthma and atopic dermatitis [1] - CanSino Biologics (06185) increased nearly 5% as it announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 2 - Kingsray Biotechnology (01548) rebounded over 4.48% following the financial performance disclosure of its joint venture Legend Biotech for the third quarter ending September 30, 2025 [2] - Fuhong Hanlin (02696) rose over 5.2% after its PD-1 antibody drug, Surufilumab injection, was proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [2] - Yidu International Holdings (00259) increased over 6% amid uncertainty regarding the impact of an undisclosed event on its financial statements for the year ending March 31, 2025 [2] Group 3 - Reshaping Energy (02570) surged nearly 60%, with a rise of 55.03%, following announcements from the National Energy Administration encouraging the use of green hydrogen in coal chemical projects and plans to promote over 2,000 hydrogen vehicles in Shandong Province [3] - Laika Pharmaceuticals-B (02105) saw a reverse increase of over 10.3% after granting Qilu Pharmaceutical exclusive rights for research, development, and commercialization of the breast cancer candidate drug LAE002 (afuresertib) in China [3] Group 4 - WMCH GLOBAL (08208) resumed trading with a rise of over 50%, increasing by 57.45% after announcing the sale of approximately 384 million shares, representing about 53.297% of its issued share capital [4] Group 5 - U.S. stock market opened lower, with the Nasdaq dropping 2.04%, as major tech stocks like Nvidia, AMD, and Tesla saw declines [5] - Tencent reached an agreement with Apple regarding payment processing for WeChat mini-games, potentially opening new revenue streams for Apple [5] - Mangoceuticals (MGRX.US) plummeted 32.39% after announcing partnerships with Eli Lilly and Novo Nordisk to provide users with weight loss medications [6] - Fannie Mae (FNMA.US) fell 9.82%, with a two-day cumulative drop of 20%, amid investigations into the actions of the Federal Housing Finance Agency director [6] - Disney (DIS.US) dropped 7.75% despite strong performance in streaming and theme parks, as upcoming major film releases are expected to impact first-quarter performance [6]

Core Viewpoint - The company has received clinical trial approval for its long-acting bispecific antibody QX027N, which is intended for the treatment of asthma and atopic dermatitis, marking a significant advancement in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The clinical trial approval was granted by the National Medical Products Administration, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N represents an important achievement in the company's bispecific antibody research and signifies further progress in its strategic layout for respiratory and skin diseases [1] - The company aims to address the clinical needs of millions of asthma and atopic dermatitis patients globally by continuing to advance innovative therapies for more effective, safer, and more convenient treatment options [1]

Core Viewpoint - The company, Qianxin Biologics-B (02509), has received clinical trial implicit approval from the National Medical Products Administration for its self-developed long-acting bispecific antibody QX027N, aimed at treating asthma and atopic dermatitis, marking a significant step in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The candidate drug QX027N represents an important achievement in the company's bispecific antibody research and signifies further progress in its collaborative layout in respiratory and dermatological disease areas [1] - The clinical approval addresses the urgent clinical needs of millions of asthma and atopic dermatitis patients worldwide, indicating the company's commitment to advancing innovative therapies [1] - The company aims to provide more efficient, safer, and more convenient treatment options for patients through continuous development and clinical translation of innovative therapies [1]

Core Viewpoint - The company has received clinical trial approval for its long-acting bispecific antibody QX027N, which is intended for the treatment of asthma and atopic dermatitis, marking a significant advancement in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The National Medical Products Administration has granted clinical trial implicit approval for QX027N, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N represents a key achievement in the company's bispecific antibody research and signifies further progress in its strategic focus on respiratory and dermatological diseases [1] - The company aims to address the clinical needs of hundreds of millions of asthma and atopic dermatitis patients globally by advancing innovative therapies for more effective, safer, and more convenient treatment options [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 承董事會命 江蘇荃信生物醫藥股份有限公司 董事會主席及執行董事 裘霽宛先生 長效雙抗QX027N獲得兩項臨床試驗默示許可 本 公 告 乃 由 江 蘇 荃 信 生 物 醫 藥 股 份 有 限 公 司（「本公司」）自 願 刊 發，以 向 股 東 及 潛 在投資者提供本公司最新的業務發展狀況。 本 公 司 董 事 會（「 董事會 」）欣 然 宣 佈， 本 公 司 自 主 研 發 的 長 效 雙 抗QX027N注 射 液 獲 得 國 家 藥 品 監 督 管 理 局 藥 品 審 評 中 心 的 臨 床 試 驗 默 示 許 可（ 受 理 號： CXSL2500757，CXSL2500758），擬 用 於 治 療 哮 喘 及 特 應 性 皮 炎。該 候 選 藥 物 的 臨 床 許可標誌著本公司在自免及過敏疾病領域的創新雙抗矩 陣 正式邁入臨床階段。 QX02 ...